title: [Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].
abstract: Results of a neurochemical study of the effects of the new anxiolytic drugs afobazole and ladasten on the synthesis and metabolism of monoamines and their metabolites determined by HPLC on the model of monoamine synthesis blockade induced by NSD-1015 (aromatic L-amino acid decarboxylase) in the brain structures of Wistar rats are reported. A decrease in the levels of DOPAC in hypothalamus and HVA in striatum after afobazole injection may be evidence of an inhibitory action of this drug on the activity of monoamine oxidase (MAO-A), which is the main enzyme involved in dopamine biodegradation. Afobazole was also found to increase the content of serotonin (5-HT) as well as its precursor (5-OTP) and its main metabolite (5-HIAA) in hypothalamus by up to 50, 60 and 50%, respectively, which confirms a hypothesis that this anxiolytic drug can modulate the activity of tryptophan hydroxylase (5-OTP synthesis enzyme). In contrast to afobazole, ladasten demonstrated the ability to increase the level of L-DOPA (a dopamine precursor) in virtually all functional structures of the brain (except for hippocamp), which may support the hypothesis suggestion concerning a predominant action of this drug on the activity of tyrosine hydroxylase. Ladasten exhibited selectivity with respect to the dopaminergic system and affected only parameters of the dopamine metabolism, in particular, by increasing the HVA content in nucleus accumbens and decreasing it in the hypothalamus. The drug also affected the dopamine turnover parameters, producing an increase in both HVA/dopamine ratio in nucleus accumbens and DOPAC/dopamine ratio in hippocamp.
authors.forename: A I
authors.initials: AI
authors.lastname: Davydova
authors.forename: P M
authors.initials: PM
authors.lastname: Klodt
authors.forename: V S
authors.initials: VS
authors.lastname: Kudrin
authors.forename: E A
authors.initials: EA
authors.lastname: Kuznetsova
authors.forename: V B
authors.initials: VB
authors.lastname: Narkevich
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001562:Benzimidazoles / Q000494:pharmacology*; D015306:Biogenic Monoamines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D006834:Hydrazines / Q000494:pharmacology*; D008297:Male; D009025:Morpholines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001562:Benzimidazoles; D015306:Biogenic Monoamines; D006834:Hydrazines; D009025:Morpholines; C493151:N-(2-adamantyl)-N-p-bromophenylamine; C004297:3-hydroxybenzylhydrazine; D000218:Adamantane